Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacteremia | 3 | 2019 | 420 | 0.850 |
Why?
|
| Urticaria | 1 | 2023 | 19 | 0.780 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2023 | 31 | 0.780 |
Why?
|
| Pneumonia | 2 | 2023 | 336 | 0.700 |
Why?
|
| Ocular Motility Disorders | 1 | 2021 | 35 | 0.680 |
Why?
|
| Eye Movements | 1 | 2021 | 61 | 0.680 |
Why?
|
| Dialysis Solutions | 1 | 2020 | 16 | 0.640 |
Why?
|
| Candida glabrata | 1 | 2020 | 18 | 0.630 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2019 | 90 | 0.620 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2019 | 823 | 0.620 |
Why?
|
| Peritonitis | 1 | 2020 | 74 | 0.620 |
Why?
|
| Gram-Negative Bacteria | 2 | 2019 | 72 | 0.610 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2024 | 231 | 0.610 |
Why?
|
| Candidiasis | 1 | 2020 | 128 | 0.580 |
Why?
|
| Peritoneal Dialysis | 1 | 2020 | 129 | 0.560 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2016 | 17 | 0.510 |
Why?
|
| Shoulder Pain | 1 | 2016 | 21 | 0.500 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 42 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 2519 | 0.380 |
Why?
|
| Fever | 3 | 2020 | 309 | 0.340 |
Why?
|
| Blood Culture | 2 | 2019 | 36 | 0.290 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 144 | 0.290 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 2 | 2020 | 73 | 0.290 |
Why?
|
| Orbital Cellulitis | 1 | 2024 | 15 | 0.220 |
Why?
|
| Child | 10 | 2024 | 25299 | 0.200 |
Why?
|
| Travel | 2 | 2015 | 123 | 0.200 |
Why?
|
| Penicillins | 1 | 2023 | 154 | 0.190 |
Why?
|
| Skull Fracture, Depressed | 1 | 2021 | 1 | 0.180 |
Why?
|
| Bites and Stings | 1 | 2021 | 27 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 1 | 2024 | 1484 | 0.170 |
Why?
|
| Skull Fractures | 1 | 2021 | 47 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 2 | 2019 | 86 | 0.170 |
Why?
|
| Craniocerebral Trauma | 1 | 2021 | 138 | 0.160 |
Why?
|
| Child, Preschool | 6 | 2024 | 14463 | 0.160 |
Why?
|
| Staphylococcal Infections | 1 | 2024 | 565 | 0.150 |
Why?
|
| Infant | 6 | 2024 | 12808 | 0.150 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 66 | 0.150 |
Why?
|
| Infliximab | 1 | 2019 | 65 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 209 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 131 | 0.140 |
Why?
|
| Humans | 15 | 2024 | 127335 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 293 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2019 | 146 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 750 | 0.130 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2016 | 19 | 0.130 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2016 | 56 | 0.120 |
Why?
|
| Diarrhea | 2 | 2015 | 306 | 0.120 |
Why?
|
| Malassezia | 1 | 2015 | 6 | 0.120 |
Why?
|
| Achromobacter denitrificans | 1 | 2015 | 2 | 0.120 |
Why?
|
| Thienamycins | 1 | 2015 | 12 | 0.120 |
Why?
|
| Baclofen | 1 | 2015 | 43 | 0.110 |
Why?
|
| Typhoid Fever | 1 | 2015 | 18 | 0.110 |
Why?
|
| Salmonella typhi | 1 | 2015 | 21 | 0.110 |
Why?
|
| Female | 10 | 2024 | 68638 | 0.110 |
Why?
|
| Vancomycin | 1 | 2016 | 221 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2075 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 249 | 0.110 |
Why?
|
| Meningitis, Bacterial | 1 | 2015 | 96 | 0.110 |
Why?
|
| Hospitalization | 1 | 2023 | 1880 | 0.110 |
Why?
|
| Parenteral Nutrition | 1 | 2015 | 214 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1235 | 0.100 |
Why?
|
| Adolescent | 6 | 2024 | 20151 | 0.090 |
Why?
|
| Serum Amyloid A Protein | 2 | 2002 | 22 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 2 | 2002 | 36 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 924 | 0.090 |
Why?
|
| Apolipoproteins | 2 | 2002 | 70 | 0.090 |
Why?
|
| Global Health | 1 | 2016 | 609 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2019 | 6241 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1867 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2016 | 776 | 0.090 |
Why?
|
| Disease Progression | 1 | 2016 | 2120 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 264 | 0.080 |
Why?
|
| Phenotype | 1 | 2019 | 4308 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6695 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5150 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2016 | 3589 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12572 | 0.060 |
Why?
|
| Young Adult | 1 | 2019 | 9698 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 1422 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2002 | 82 | 0.050 |
Why?
|
| Male | 4 | 2024 | 62795 | 0.050 |
Why?
|
| Endocytosis | 1 | 2002 | 120 | 0.050 |
Why?
|
| Debridement | 1 | 2021 | 89 | 0.040 |
Why?
|
| Aged | 1 | 2019 | 20433 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 614 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 73 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 72 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2234 | 0.040 |
Why?
|
| Middle Aged | 1 | 2019 | 27818 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 134 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 246 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 292 | 0.040 |
Why?
|
| Adult | 1 | 2019 | 30544 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 326 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 223 | 0.030 |
Why?
|
| beta-Lactamases | 1 | 2019 | 211 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1147 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1597 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2015 | 36 | 0.030 |
Why?
|
| Muscle Relaxants, Central | 1 | 2015 | 37 | 0.030 |
Why?
|
| Williams Syndrome | 1 | 2015 | 41 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2015 | 129 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 2015 | 101 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 135 | 0.030 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2015 | 79 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2024 | 17068 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1206 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 733 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 251 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 303 | 0.020 |
Why?
|
| Echocardiography | 1 | 2019 | 1115 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 1378 | 0.020 |
Why?
|
| Skin Diseases, Infectious | 1 | 2013 | 24 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 848 | 0.020 |
Why?
|
| Jaundice | 1 | 2013 | 27 | 0.020 |
Why?
|
| Skin | 1 | 2015 | 517 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 334 | 0.020 |
Why?
|
| Malaria | 1 | 2013 | 97 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2013 | 104 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 825 | 0.020 |
Why?
|
| Microscopy, Confocal | 2 | 2002 | 361 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6163 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8366 | 0.020 |
Why?
|
| Animals | 3 | 2021 | 33197 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 10612 | 0.010 |
Why?
|
| Congo Red | 1 | 2002 | 7 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2002 | 65 | 0.010 |
Why?
|
| Fluorescence | 1 | 2002 | 97 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 260 | 0.010 |
Why?
|
| Xanthenes | 1 | 2001 | 6 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 2001 | 73 | 0.010 |
Why?
|
| Amyloidosis | 1 | 2001 | 71 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 248 | 0.010 |
Why?
|
| United States | 1 | 2015 | 11386 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1598 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 1663 | 0.010 |
Why?
|
| Mice | 2 | 2002 | 17686 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 4513 | 0.010 |
Why?
|